Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: Pharma
As AstraZeneca prepares for the impact of the U.S. “most-favored nation” policy, CEO Pascal Soriot…
Three years after AbbVie lost exclusive rights to its immunology blockbuster Humira, leaving it on…
GSK’s first quarter, under CEO Luke Miels, saw its flagship shingles vaccine Shingrix set a…
Sales of the eye disease drug continue to decline as regulatory delays continue to plague…
Nearly three years after the FDA approved Pfizer’s bispecific antibody Ellexfio as a late-stage treatment…
Chiesi sets aside $1.9 billion to strengthen rare disease offerings with acquisition of KalVista
By healthadmin
As Ectory approaches one year since its FDA approval, Italy’s Chiesi Group is moving to…
Novartis Chief Executive Vasu Narasimhan said Europe needed a “complete rethink” of how medicines are…
Pfizer’s decision to agree to the last of three settlements to delay the launch of…
The FDA released a briefing document detailing its concerns about AstraZeneca cancer drug distributor and…
Rocket Pharmaceuticals sold its FDA Rare Pediatric Disease Priority Review Voucher (PRV) in a $180…